New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
Top Cited Papers
Open Access
- 9 November 2023
- journal article
- review article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (11) , e007530
Abstract
Chronic inflammation has been recognized as a canonical cancer hallmark. It is orchestrated by cytokines, which are master regulators of the tumor microenvironment (TME) as they represent the main communication bridge between cancer cells, the tumor stroma, and the immune system. Interleukin (IL)-6 represents a keystone cytokine in the link between inflammation and cancer. Many cytokines from the IL-6 family, which includes IL-6, oncostatin M, leukemia inhibitory factor, IL-11, IL-27, IL-31, ciliary neurotrophic factor, cardiotrophin 1, and cardiotrophin-like cytokine factor 1, have been shown to elicit tumor-promoting roles by modulating the TME, making them attractive therapeutic targets for cancer treatment. The development of immune checkpoint blockade (ICB) immunotherapies has radically changed the outcome of some cancers including melanoma, lung, and renal, although not without hurdles. However, ICB shows limited efficacy in other solid tumors. Recent reports support that chronic inflammation and IL-6 cytokine signaling are involved in resistance to immunotherapy. This review summarizes the available preclinical and clinical data regarding the implication of IL-6-related cytokines in regulating the immune TME and the response to ICB. Moreover, the potential clinical benefit of combining ICB with therapies targeting IL-6 cytokine members for cancer treatment is discussed.Keywords
Funding Information
- Instituto de Salud Carlos III (CP18/00076, P21/01208)
- Roche España
- CIC biomaGUNE
- Abyntek Biopharma
- Fundación Sociedad Española de Oncología Médica (Beca SEOM-FESEO 2021)
- Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza
- Fundación Gangoiti (N/A)
- Ikerbasque, Basque Foundation for Science (N/A)
This publication has 153 references indexed in Scilit:
- LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic markerNature Medicine, 2012
- Oncostatin M Promotes Mammary Tumor Metastasis to Bone and Osteolytic Bone DegradationGenes & Cancer, 2012
- Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell linesBMC Cancer, 2011
- Interleukin-6 in bone metastasis and cancer progressionEuropean Journal of Cancer, 2010
- TGF-β Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human GlioblastomaCancer Cell, 2009
- Cancer-related inflammationNature, 2008
- STAT3 and STAT1 mediate IL-11–dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant miceJournal of Clinical Investigation, 2008
- Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer CellsClinical Cancer Research, 2006
- Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblastsCellular Signalling, 2004
- Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasisOncogene, 2004